|
| miRNA | Targets | Biological effects of dysregulation | Comments on dysregulation |
|
| Downregulated |
|
| let-7a, b, c, f | Ras, CDK6, cyclin A2 | Ras oncogene activation, cell proliferation, angiogenesis | Normally, let-7 is a master regulator of cell proliferation |
| mir-26a | TGF | TGF overexpression, angiogenesis | Greater downregulation in postweanling female mice |
| mir-30a | EFG pathway, NF-κB inhibitors, CDC40 | Cell cycle progression, cell adhesion, protein repair, EFG activation, stress response (NF-κB activation) | Downregulated in both humans and rats |
| mir-30c | EFG pathway, NF-κB inhibitors, CDC41 | Chemoresistance, cell cycle progression, cell adhesion, protein repair, EFG activation, stress response (NF-κB activation) | Downregulation leads to chemoresistance mediated through MDR-1 |
| mir-34 a–c | CDK4, CDK6, cyclin E2, and E2F3 | Cell cycle arrest inhibited | Mutations in p53 can lead to its downregulation |
| mir-122a | heme-oxygenase 1 | Increased antioxidant activity in liver and lungs | Involved in stress response |
| mir-125a | ERBB7 (gene for EGFR) | ERBB7 oncogene activation | Maps to fragile site with G/U polymorphism |
| mir-140 | p53 pathway | Cell cycle arrest inhibited | Greater downregulated in postweanling female mice |
| mir-345 | Ras pathway | Ras oncogene activation, cell proliferation | Downregulation is persistent for at least one week after cessation |
|
| Upregulated |
|
| mir-294 | Zinc finger protein 697, AT-rich interactive domain 4A | Increase in transcription | Upregulated 10.4-fold in Izzotti et al. [8]. |
|
